SCHEMBL6762830

SCHEMBL6762830

O=C(CCCCCCCCCCCNc1ccc([N+](=O)[O-])c2nonc12)OC[C@H](O)CO

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSTM2 P28161 3/20 0.64
▸ HRH3 Q9Y5N1 2/20 0.52
▸ S1PR1 P21453 3/20 0.52
▸ S1PR3 Q99500 3/20 0.52
▸ S1PR4 O95977 2/20 0.52
▸ S1PR5 Q9H228 2/20 0.52
▸ GSTP1 P09211 2/20 0.46
▸ SUCNR1 Q9BXA5 2/20 0.46
▸ MYC P01106 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ MIF P14174 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4645759 0.84 GSTM2 (0.44) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL6762713 0.84 GSTM2 (0.57) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL6759014 0.84 GSTM2 (0.57) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL6759054 0.82 GSTM2 (0.56) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL31576805 0.82 GSTM2 (0.62) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL3424607 0.81 PRKCA (0.55) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL31751965 0.81 PRKCA (0.55) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL15515612 0.81 GSTM2 (0.76) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL285019 0.81 GSTM2 (0.76) GSTM2HRH3S1PR1S1PR3S1PR4
SCHEMBL459120 0.81 GSTM2 (0.76) GSTM2HRH3S1PR1S1PR3S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6783949-B1 REACTING FLUORESCENTLY LABELED FATTY ACID WITH 2,3-EPOXYPROPANOL TO FORM MONOGLYCERIDE WHICH IS SUBJECTED TO ULTRASONIC TREATMENT WITH PHOSPHOLIPIDS; DRUG SCREENING; FOR DETECTING METABOLIC DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-31 — — US disclosed
Send feedback